Abstract Number: 710 • 2018 ACR/ARHP Annual Meeting
An Analysis of Cell-of-Origin in Diffuse Large B-Cell Lymphoma in Systemic Lupus Erythematosus, Including Molecular and Clinical Factors Associated with Survival
Background/Purpose: Systemic lupus erythematosus (SLE) is associated with increased risk of diffuse large B-cell lymphoma (DLBCL). DLBCL is routinely classified by cell-of-origin (COO), with non-germinal…Abstract Number: 814 • 2018 ACR/ARHP Annual Meeting
NON Diffuse SSc, Peripheral Neuropathy, Concomitant Sjogren Syndrome and ANTI-RNA Polymerase III Represent Risk Factors for the Higher Frequency of Cancer in a Large Single Cohort of Patients with Systemic Sclerosis
Background/Purpose: A higher prevalence of cancer has been described in patients with systemic sclerosis (SSc), but the magnitude of this risk and the type of…Abstract Number: 880 • 2018 ACR/ARHP Annual Meeting
Serum Cytokine and Chemokine Concentrations Predict Incident Cancer in US Veterans with Rheumatoid Arthritis
Background/Purpose: The immune system plays a critical protective role in cancer (CA) development. Perturbations in immune signaling, including cytokine dysregulation, may disrupt this homeostatic balance.…Abstract Number: 1522 • 2018 ACR/ARHP Annual Meeting
Time Dependent Effect of Biologic Therapy on Overall Survival in Patients with Rheumatoid Arthritis and Cancer
Background/Purpose: Biologic disease-modifying anti-rheumatic drugs (bDMARDs) are commonly used in the treatment of rheumatoid arthritis (RA). But the use of bDMARDs in patients with RA…Abstract Number: 2143 • 2018 ACR/ARHP Annual Meeting
Lymphoproliferative Malignancy in Psoriatic Arthritis and the Role of Systemic Immunosuppressive Therapies
Background/Purpose: Psoriatic arthritis (PsA) is a systemic inflammatory disease that can have musculoskeletal (PsA-MsK) or concurrent MsK and skin (PsA-MsK/skin) manifestations, and the skin disease…Abstract Number: 2160 • 2018 ACR/ARHP Annual Meeting
Effect of the Metabolic Syndrome on Incident Vascular Events and Mortality in Four Rheumatic Diseases: An 8-Year Longitudinal Analysis
Background/Purpose: To study the effect of the metabolic syndrome (MetS) on incident vascular events and mortality in 4 rheumatic diseases over an 8-years’ follow-up. Methods:…Abstract Number: 2991 • 2018 ACR/ARHP Annual Meeting
Malignancies In Giant Cell Arteritis- A Population-Based Cohort Study
Background/Purpose: To investigate the cancer risk in patients with biopsy-proven giant cell arteritis (GCA). Methods: The study population consisted of 830 patients (74 % women)…Abstract Number: 364 • 2018 ACR/ARHP Annual Meeting
Elevated sCD40L As a Predictive Biomarker of Immune-Related Adverse Events in Patients Receiving Immune Checkpoint Inhibitors
Background/Purpose: The clinical use of immune checkpoint inhibitors (ICI) has led to outstanding clinical outcomes in previously refractory cancers, but ICI have also been associated…Abstract Number: 11L • 2017 ACR/ARHP Annual Meeting
Risk of Second Malignant Neoplasm and Mortality in Rheumatoid Arthritis Patients Treated with Biological Dmards: A Danish Population-Based Cohort Study
Background/Purpose: The safety of treatment with biological DMARDs (bDMARDs) has been carefully studied for the past 15 years, however, it is still largely unknown whether…Abstract Number: 849 • 2017 ACR/ARHP Annual Meeting
Tumor TIF1 Mutations and Loss of Heterozygosity Related to Cancer Associated Myositis
Background/Purpose: To analyze the influence of genetic alterations and differential expression of the TIF1 genes in the pathophysiology of cancer-associated myositis (CAM). Methods: Whole exome…Abstract Number: 853 • 2017 ACR/ARHP Annual Meeting
Anti-TIF-1 Antibody Positivity Is Associated with a Five-Fold Increase in Cancer Risk in the Idiopathic Inflammatory Myopathies
Background/Purpose: There is an increased cancer risk associated with the idiopathic inflammatory myopathies (IIM). Studies have identified that positivity for the autoantibody against transcriptional intermediary…Abstract Number: 1146 • 2017 ACR/ARHP Annual Meeting
Associations between Gout and Cancer in an Nhanes Cohort
Background/Purpose: Gout is the most common inflammatory disease in the United States (US), affecting more than 4% of the population. Although uric acid (UA) can…Abstract Number: 1227 • 2017 ACR/ARHP Annual Meeting
Osteoporosis and Breast Cancer: Can FRAX-Based Risk Factors Accurately Predict Further Fractures at This Setting?
Background/Purpose: Women with breast cáncer (BC) are at risk for the development of bone loss and osteoporosis (OP) mainly due to adjuvant therapies, as aromatase…Abstract Number: 1228 • 2017 ACR/ARHP Annual Meeting
Postmenopausal Breast Cancer Patients on Aromatase Inhibitor Therapy and Their Increased Risk of Fragility Fracture
Background/Purpose: Postmenopausal women with breast cancer have higher osteoporosis risk due to declining estrogen levels and use of aromatase inhibitors (AIs). The American Society of…Abstract Number: 1606 • 2017 ACR/ARHP Annual Meeting
Cancer in an SLE Inception Cohort: Smoking May out-Perform Tumor Markers As a Risk Predictor
Background/Purpose: We assessed incident cancers in a large inception SLE cohort, and examined demographic and clinical factors, including tumor-related autoantibodies against proliferating cell nuclear antigen…